Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'Healthy longevity with rapamycin (LONGER)'. The following are the other relevant details related t... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'Efficacy and safety of LUCONAC ® External Solution for the treatment of Onychomycosis in anopen la... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, participant- and investigator - blinded, placebo-controlled, phase 2a s... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, m... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'Using AS01 adjuvant to improve immune response in older adults through trained immunity'. The foll... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose,and Pre... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab... Read More
Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Invest... Read More